A Phase II Open-Label, Multiple-Dose Study of Intracavitary Administered 131-I-TM-601 in Adult Patients With Recurrent High-Grade Glioma

Trial Profile

A Phase II Open-Label, Multiple-Dose Study of Intracavitary Administered 131-I-TM-601 in Adult Patients With Recurrent High-Grade Glioma

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Nov 2009

At a glance

  • Drugs TM 601 I-131 (Primary)
  • Indications Glioma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 02 Nov 2009 Final results will be presented at the 2009 Joint Meeting of the Society for Neuro-Oncology and the AANS/CNS Section on Tumors, according to a TransMolecular media release.
    • 24 Oct 2009 Status changed from active, no longer recruiting to completed, according to a TransMolecular media release.
    • 08 Apr 2009 Planned end date changed from 1 Dec 2008 to 1 Aug 2009 as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top